Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Recurrent Ovarian Cancer (PROC)”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07741630
What this trial is testing

Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
PROC
Peking University Third Hospital 20
Early research (Phase 1)Looking for participantsNCT07444814
What this trial is testing

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Who this might be right for
Endometrial CancerOvarian CancerOvarian Cancer Metastatic+4 more
Whitehawk Therapeutics, Inc. 226
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06600841
What this trial is testing

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer (PROC)Immunotherapy
Fujian Cancer Hospital 37
Early research (Phase 1)Not Yet RecruitingNCT07462468
What this trial is testing

Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer (PROC)
WestVac Biopharma Co., Ltd. 36
Testing effectiveness (Phase 2)Study completedNCT05044871
What this trial is testing

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Tongji Hospital 108
Post-approval studies (Phase 4)Not Yet RecruitingNCT07075250
What this trial is testing

Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study

Who this might be right for
Platinum-resistant Ovarian Cancer (PROC)
Peking University People's Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07314619
What this trial is testing

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer (PROC)
The First Affiliated Hospital of Zhengzhou University 30